Wordt geladen...
Does the omission of vincristine in patients with diffuse large B cell lymphoma affect treatment outcome?
The standard treatment for diffuse large B cell lymphoma (DLBCL) is rituximab with CHOP (cyclophosphamide, doxorubicin, vincristine (VCR), and prednisone). Maintaining high dose intensity of cytotoxic treatment has been associated with better outcome but little is known about the role of maintaining...
Bewaard in:
| Gepubliceerd in: | Ann Hematol |
|---|---|
| Hoofdauteurs: | , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Springer Berlin Heidelberg
2018
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6182738/ https://ncbi.nlm.nih.gov/pubmed/30091025 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00277-018-3437-z |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|